BioCentury
ARTICLE | Clinical News

HCT-3012: Began Phase II testing

January 29, 2001 8:00 AM UTC

NicOx S.A. (NM:Nicox), Sophia-Antipolis, France Product: HCT-3012 Business: Autoimmune/Inflammation Therapeutic category: NSAID, Nitric oxide Target: Cyclooxygenase (COX) enzymes Description: Nitric o...